US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Alamar Biosciences (ALMR): Scarcity and Growth Power Strong First-Day Rally for Proteomics Platform

Alamar Biosciences (ALMR): Bio-Platform Company Scales, Draws Heavy IPO Interest

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

IPOs and Secondary Offerings

Equity Capital Markets

Alamar Biosciences / Equity Capital Markets

<ul>
<li>Shares remain above the IPO price, despite falling 38.8% from their October 6 intraday peak.</li>
<li>Second-Quarter revenue increased 82%, with consumables growth and improving gross margins supporting the platform’s commercial traction.</li>
<li>Leadership additions did not replace the CEO; premium valuation and possible future share supply warrant attention.</li>
</ul>


Shares remain above the IPO price, despite falling 38.8% from their October 6 intraday peak.
Second-Quarter revenue increased 82%, with consumables growth and improving gross margins supporting the platform’s commercial traction.
Leadership additions did not replace the CEO; premium valuation and possible future share supply warrant attention.


Alamar Biosciences (ALMR): Down From the Peak, Still Above the Offering